A Pilot Clinical Study on the Prognostic Relevance of Plasmatic Exosomes Levels in Oral Squamous Cell Carcinoma Patients
To evaluate the relationship between the plasmatic CD63 and CAV1 positive exosome levels, in patients with OSCC before and after surgical treatment and to correlate it with their overall survival. A double-blind pilot study over 10 patients OSCC and T4 stage without distant metastases or local bone...
Gespeichert in:
| Veröffentlicht in: | Cancers 2019-03, Vol.11 (3), p.429 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | 429 |
| container_title | Cancers |
| container_volume | 11 |
| creator | Rodríguez Zorrilla, Samuel Pérez-Sayans, Mario Fais, Stefano Logozzi, Mariantonia Gallas Torreira, Mercedes García García, Abel |
| description | To evaluate the relationship between the plasmatic CD63 and CAV1 positive exosome levels, in patients with OSCC before and after surgical treatment and to correlate it with their overall survival.
A double-blind pilot study over 10 patients OSCC and T4 stage without distant metastases or local bone invasion has been performed. The average follow-up period was 37.64 months (34.3⁻40.84). We obtained 2 plasma tubes of 1 mL each before surgery and 7 days after surgery. Before performing the immunocapture-based analysis, EVs (Extracellular Vesicles) were isolated from the plasma and characterized with western blot analysis.
Mean values of CD63 positive plasmatic exosomes (EXO-CD63) after surgery decreased from 750.88 ± 286.67 to 541.71 ± 244.93 (
= 0.091). On the other hand, CAV-1 positive plasmatic exosomes (EXO-CAV-1) increased after surgery from 507 ± 483.39 to 1120.25 ± 1151.17 (
= 0.237). Patients with EXO-CD63 levels lower than the mean global value before the surgery had a survival of 36.04 months compared with the group with EXO-CD63 higher than the average who only survived 12.49 ± 1.67 months from the diagnosis,
= 0.225. When EXO-CAV-1 levels before surgery was lower than the average (813.94 ± 801.21) overall survival was 24.69 ± 22.23 months in contrast when it was higher that was only 11.64 months,
= 0.157. Patients with lower EXO-CD63 levels after surgery lived an average of 23.84 ± 23.9 months, while those with higher plasmatic levels of EXO-CD63 live 13.35 months,
= 0.808. When EXO-CAV-1 levels after surgery were lower, the average overall survival was 20.344 ± 15.40 months, in contrast when the EXO-CAV-1 levels were higher showing rather an estimate survival expectation of 1.64 months.
Surgical treatment induced a dramatic reduction of the plasmatic levels of exosomes expressing CD63 as early as 1 week after resection. This first result suggests that the tumour mass is responsible of the high levels of circulating exosomes detected in cancer patients. At the same time point exosome expressing CAV-1 increased, possibly due to the inflammatory reaction immediately after surgery. Lastly, statistical analysis showed that lower levels of plasmatic exosomes both before and after surgery correlated with a better life expectancy of OSCC patients. Hopefully, this approach will prove useful in the clinical follow-up of cancer patients. |
| doi_str_mv | 10.3390/cancers11030429 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6468603</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2199184066</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-69964f3295fa893579dc9e6ed4bb58ccc595413f67a8f94e5d564f5237074af83</originalsourceid><addsrcrecordid>eNpdkUtLJDEUhYM4qPS4dicBN256zDuVjSBFOzPQYDOPdUinUhpJJZpUNfrvTaEjjtkkJN89954cAE4w-kapQhfWROtywRhRxIjaA0cESbIUQrH9D-dDcFzKPaqLUiyFPACHFCksORVH4OkKbnxII2yDj96aAH-PU_cMU4TjnYObnG5jKqO38JcLbjd3hKmHm2DKYObr1VMqaXAFrt3OhQJ9hDd5lnmczJCmAlsXAmxNtj6mwcBNrXJxLF_Bl96E4o7f9gX4e7360_5Yrm--_2yv1kvLCB6XQinBekoU702jKJeqs8oJ17HtljfWWq44w7QX0jS9Yo53vPKcUIkkM31DF-DyVfdh2g6us7V3HU8_ZD-Y_KyT8fr_l-jv9G3aacFEI-qXLcD5m0BOj5Mrox58sdWUia760wQrhRuGhKjo2Sf0Pk05VnuacCa5oJjM1MUrZXMqJbv-fRiM9Bys_hRsrTj96OGd_xcjfQF8MqCo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2547563126</pqid></control><display><type>article</type><title>A Pilot Clinical Study on the Prognostic Relevance of Plasmatic Exosomes Levels in Oral Squamous Cell Carcinoma Patients</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Rodríguez Zorrilla, Samuel ; Pérez-Sayans, Mario ; Fais, Stefano ; Logozzi, Mariantonia ; Gallas Torreira, Mercedes ; García García, Abel</creator><creatorcontrib>Rodríguez Zorrilla, Samuel ; Pérez-Sayans, Mario ; Fais, Stefano ; Logozzi, Mariantonia ; Gallas Torreira, Mercedes ; García García, Abel</creatorcontrib><description>To evaluate the relationship between the plasmatic CD63 and CAV1 positive exosome levels, in patients with OSCC before and after surgical treatment and to correlate it with their overall survival.
A double-blind pilot study over 10 patients OSCC and T4 stage without distant metastases or local bone invasion has been performed. The average follow-up period was 37.64 months (34.3⁻40.84). We obtained 2 plasma tubes of 1 mL each before surgery and 7 days after surgery. Before performing the immunocapture-based analysis, EVs (Extracellular Vesicles) were isolated from the plasma and characterized with western blot analysis.
Mean values of CD63 positive plasmatic exosomes (EXO-CD63) after surgery decreased from 750.88 ± 286.67 to 541.71 ± 244.93 (
= 0.091). On the other hand, CAV-1 positive plasmatic exosomes (EXO-CAV-1) increased after surgery from 507 ± 483.39 to 1120.25 ± 1151.17 (
= 0.237). Patients with EXO-CD63 levels lower than the mean global value before the surgery had a survival of 36.04 months compared with the group with EXO-CD63 higher than the average who only survived 12.49 ± 1.67 months from the diagnosis,
= 0.225. When EXO-CAV-1 levels before surgery was lower than the average (813.94 ± 801.21) overall survival was 24.69 ± 22.23 months in contrast when it was higher that was only 11.64 months,
= 0.157. Patients with lower EXO-CD63 levels after surgery lived an average of 23.84 ± 23.9 months, while those with higher plasmatic levels of EXO-CD63 live 13.35 months,
= 0.808. When EXO-CAV-1 levels after surgery were lower, the average overall survival was 20.344 ± 15.40 months, in contrast when the EXO-CAV-1 levels were higher showing rather an estimate survival expectation of 1.64 months.
Surgical treatment induced a dramatic reduction of the plasmatic levels of exosomes expressing CD63 as early as 1 week after resection. This first result suggests that the tumour mass is responsible of the high levels of circulating exosomes detected in cancer patients. At the same time point exosome expressing CAV-1 increased, possibly due to the inflammatory reaction immediately after surgery. Lastly, statistical analysis showed that lower levels of plasmatic exosomes both before and after surgery correlated with a better life expectancy of OSCC patients. Hopefully, this approach will prove useful in the clinical follow-up of cancer patients.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers11030429</identifier><identifier>PMID: 30917536</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Biomarkers ; Calcium channels (voltage-gated) ; Caveolin-1 ; CD63 antigen ; Clinical trials ; Cloning ; Exosomes ; Inflammation ; Life span ; Lymphatic system ; Medical research ; Metastases ; Metastasis ; Oral cancer ; Oral squamous cell carcinoma ; Patients ; Plasma ; Squamous cell carcinoma ; Statistical analysis ; Surgery ; Tumors</subject><ispartof>Cancers, 2019-03, Vol.11 (3), p.429</ispartof><rights>2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 by the authors. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-69964f3295fa893579dc9e6ed4bb58ccc595413f67a8f94e5d564f5237074af83</citedby><cites>FETCH-LOGICAL-c421t-69964f3295fa893579dc9e6ed4bb58ccc595413f67a8f94e5d564f5237074af83</cites><orcidid>0000-0003-4625-3321 ; 0000-0001-5869-1025 ; 0000-0003-2196-9868</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468603/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468603/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30917536$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rodríguez Zorrilla, Samuel</creatorcontrib><creatorcontrib>Pérez-Sayans, Mario</creatorcontrib><creatorcontrib>Fais, Stefano</creatorcontrib><creatorcontrib>Logozzi, Mariantonia</creatorcontrib><creatorcontrib>Gallas Torreira, Mercedes</creatorcontrib><creatorcontrib>García García, Abel</creatorcontrib><title>A Pilot Clinical Study on the Prognostic Relevance of Plasmatic Exosomes Levels in Oral Squamous Cell Carcinoma Patients</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>To evaluate the relationship between the plasmatic CD63 and CAV1 positive exosome levels, in patients with OSCC before and after surgical treatment and to correlate it with their overall survival.
A double-blind pilot study over 10 patients OSCC and T4 stage without distant metastases or local bone invasion has been performed. The average follow-up period was 37.64 months (34.3⁻40.84). We obtained 2 plasma tubes of 1 mL each before surgery and 7 days after surgery. Before performing the immunocapture-based analysis, EVs (Extracellular Vesicles) were isolated from the plasma and characterized with western blot analysis.
Mean values of CD63 positive plasmatic exosomes (EXO-CD63) after surgery decreased from 750.88 ± 286.67 to 541.71 ± 244.93 (
= 0.091). On the other hand, CAV-1 positive plasmatic exosomes (EXO-CAV-1) increased after surgery from 507 ± 483.39 to 1120.25 ± 1151.17 (
= 0.237). Patients with EXO-CD63 levels lower than the mean global value before the surgery had a survival of 36.04 months compared with the group with EXO-CD63 higher than the average who only survived 12.49 ± 1.67 months from the diagnosis,
= 0.225. When EXO-CAV-1 levels before surgery was lower than the average (813.94 ± 801.21) overall survival was 24.69 ± 22.23 months in contrast when it was higher that was only 11.64 months,
= 0.157. Patients with lower EXO-CD63 levels after surgery lived an average of 23.84 ± 23.9 months, while those with higher plasmatic levels of EXO-CD63 live 13.35 months,
= 0.808. When EXO-CAV-1 levels after surgery were lower, the average overall survival was 20.344 ± 15.40 months, in contrast when the EXO-CAV-1 levels were higher showing rather an estimate survival expectation of 1.64 months.
Surgical treatment induced a dramatic reduction of the plasmatic levels of exosomes expressing CD63 as early as 1 week after resection. This first result suggests that the tumour mass is responsible of the high levels of circulating exosomes detected in cancer patients. At the same time point exosome expressing CAV-1 increased, possibly due to the inflammatory reaction immediately after surgery. Lastly, statistical analysis showed that lower levels of plasmatic exosomes both before and after surgery correlated with a better life expectancy of OSCC patients. Hopefully, this approach will prove useful in the clinical follow-up of cancer patients.</description><subject>Biomarkers</subject><subject>Calcium channels (voltage-gated)</subject><subject>Caveolin-1</subject><subject>CD63 antigen</subject><subject>Clinical trials</subject><subject>Cloning</subject><subject>Exosomes</subject><subject>Inflammation</subject><subject>Life span</subject><subject>Lymphatic system</subject><subject>Medical research</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Oral cancer</subject><subject>Oral squamous cell carcinoma</subject><subject>Patients</subject><subject>Plasma</subject><subject>Squamous cell carcinoma</subject><subject>Statistical analysis</subject><subject>Surgery</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkUtLJDEUhYM4qPS4dicBN256zDuVjSBFOzPQYDOPdUinUhpJJZpUNfrvTaEjjtkkJN89954cAE4w-kapQhfWROtywRhRxIjaA0cESbIUQrH9D-dDcFzKPaqLUiyFPACHFCksORVH4OkKbnxII2yDj96aAH-PU_cMU4TjnYObnG5jKqO38JcLbjd3hKmHm2DKYObr1VMqaXAFrt3OhQJ9hDd5lnmczJCmAlsXAmxNtj6mwcBNrXJxLF_Bl96E4o7f9gX4e7360_5Yrm--_2yv1kvLCB6XQinBekoU702jKJeqs8oJ17HtljfWWq44w7QX0jS9Yo53vPKcUIkkM31DF-DyVfdh2g6us7V3HU8_ZD-Y_KyT8fr_l-jv9G3aacFEI-qXLcD5m0BOj5Mrox58sdWUia760wQrhRuGhKjo2Sf0Pk05VnuacCa5oJjM1MUrZXMqJbv-fRiM9Bys_hRsrTj96OGd_xcjfQF8MqCo</recordid><startdate>20190326</startdate><enddate>20190326</enddate><creator>Rodríguez Zorrilla, Samuel</creator><creator>Pérez-Sayans, Mario</creator><creator>Fais, Stefano</creator><creator>Logozzi, Mariantonia</creator><creator>Gallas Torreira, Mercedes</creator><creator>García García, Abel</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4625-3321</orcidid><orcidid>https://orcid.org/0000-0001-5869-1025</orcidid><orcidid>https://orcid.org/0000-0003-2196-9868</orcidid></search><sort><creationdate>20190326</creationdate><title>A Pilot Clinical Study on the Prognostic Relevance of Plasmatic Exosomes Levels in Oral Squamous Cell Carcinoma Patients</title><author>Rodríguez Zorrilla, Samuel ; Pérez-Sayans, Mario ; Fais, Stefano ; Logozzi, Mariantonia ; Gallas Torreira, Mercedes ; García García, Abel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-69964f3295fa893579dc9e6ed4bb58ccc595413f67a8f94e5d564f5237074af83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Biomarkers</topic><topic>Calcium channels (voltage-gated)</topic><topic>Caveolin-1</topic><topic>CD63 antigen</topic><topic>Clinical trials</topic><topic>Cloning</topic><topic>Exosomes</topic><topic>Inflammation</topic><topic>Life span</topic><topic>Lymphatic system</topic><topic>Medical research</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Oral cancer</topic><topic>Oral squamous cell carcinoma</topic><topic>Patients</topic><topic>Plasma</topic><topic>Squamous cell carcinoma</topic><topic>Statistical analysis</topic><topic>Surgery</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rodríguez Zorrilla, Samuel</creatorcontrib><creatorcontrib>Pérez-Sayans, Mario</creatorcontrib><creatorcontrib>Fais, Stefano</creatorcontrib><creatorcontrib>Logozzi, Mariantonia</creatorcontrib><creatorcontrib>Gallas Torreira, Mercedes</creatorcontrib><creatorcontrib>García García, Abel</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rodríguez Zorrilla, Samuel</au><au>Pérez-Sayans, Mario</au><au>Fais, Stefano</au><au>Logozzi, Mariantonia</au><au>Gallas Torreira, Mercedes</au><au>García García, Abel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Pilot Clinical Study on the Prognostic Relevance of Plasmatic Exosomes Levels in Oral Squamous Cell Carcinoma Patients</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2019-03-26</date><risdate>2019</risdate><volume>11</volume><issue>3</issue><spage>429</spage><pages>429-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>To evaluate the relationship between the plasmatic CD63 and CAV1 positive exosome levels, in patients with OSCC before and after surgical treatment and to correlate it with their overall survival.
A double-blind pilot study over 10 patients OSCC and T4 stage without distant metastases or local bone invasion has been performed. The average follow-up period was 37.64 months (34.3⁻40.84). We obtained 2 plasma tubes of 1 mL each before surgery and 7 days after surgery. Before performing the immunocapture-based analysis, EVs (Extracellular Vesicles) were isolated from the plasma and characterized with western blot analysis.
Mean values of CD63 positive plasmatic exosomes (EXO-CD63) after surgery decreased from 750.88 ± 286.67 to 541.71 ± 244.93 (
= 0.091). On the other hand, CAV-1 positive plasmatic exosomes (EXO-CAV-1) increased after surgery from 507 ± 483.39 to 1120.25 ± 1151.17 (
= 0.237). Patients with EXO-CD63 levels lower than the mean global value before the surgery had a survival of 36.04 months compared with the group with EXO-CD63 higher than the average who only survived 12.49 ± 1.67 months from the diagnosis,
= 0.225. When EXO-CAV-1 levels before surgery was lower than the average (813.94 ± 801.21) overall survival was 24.69 ± 22.23 months in contrast when it was higher that was only 11.64 months,
= 0.157. Patients with lower EXO-CD63 levels after surgery lived an average of 23.84 ± 23.9 months, while those with higher plasmatic levels of EXO-CD63 live 13.35 months,
= 0.808. When EXO-CAV-1 levels after surgery were lower, the average overall survival was 20.344 ± 15.40 months, in contrast when the EXO-CAV-1 levels were higher showing rather an estimate survival expectation of 1.64 months.
Surgical treatment induced a dramatic reduction of the plasmatic levels of exosomes expressing CD63 as early as 1 week after resection. This first result suggests that the tumour mass is responsible of the high levels of circulating exosomes detected in cancer patients. At the same time point exosome expressing CAV-1 increased, possibly due to the inflammatory reaction immediately after surgery. Lastly, statistical analysis showed that lower levels of plasmatic exosomes both before and after surgery correlated with a better life expectancy of OSCC patients. Hopefully, this approach will prove useful in the clinical follow-up of cancer patients.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>30917536</pmid><doi>10.3390/cancers11030429</doi><orcidid>https://orcid.org/0000-0003-4625-3321</orcidid><orcidid>https://orcid.org/0000-0001-5869-1025</orcidid><orcidid>https://orcid.org/0000-0003-2196-9868</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2019-03, Vol.11 (3), p.429 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6468603 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Biomarkers Calcium channels (voltage-gated) Caveolin-1 CD63 antigen Clinical trials Cloning Exosomes Inflammation Life span Lymphatic system Medical research Metastases Metastasis Oral cancer Oral squamous cell carcinoma Patients Plasma Squamous cell carcinoma Statistical analysis Surgery Tumors |
| title | A Pilot Clinical Study on the Prognostic Relevance of Plasmatic Exosomes Levels in Oral Squamous Cell Carcinoma Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T17%3A37%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Pilot%20Clinical%20Study%20on%20the%20Prognostic%20Relevance%20of%20Plasmatic%20Exosomes%20Levels%20in%20Oral%20Squamous%20Cell%20Carcinoma%20Patients&rft.jtitle=Cancers&rft.au=Rodr%C3%ADguez%20Zorrilla,%20Samuel&rft.date=2019-03-26&rft.volume=11&rft.issue=3&rft.spage=429&rft.pages=429-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers11030429&rft_dat=%3Cproquest_pubme%3E2199184066%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2547563126&rft_id=info:pmid/30917536&rfr_iscdi=true |